Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2012 Dec 6;137(2):449–455. doi: 10.1007/s10549-012-2366-0

Table 1.

HER2 Hazard Ratios by HR Status and Site of Recurrence

Site HR Negative Patients HR Positive Patients p-value*
Brain 1.40 (1.00, 1.70) 2.88 (2.24, 3.71) <0.0001
Liver 1.10 (0.89, 1.40) 1.50 (1.22, 1.84) 0.31
Lung 0.72 (0.58, 0.90) 1.43 (1.12, 1.83) <0.0001
Pleura 0.62 (0.43, 0.88) 1.08 (0.76, 1.53) 0.027
Bone 0.72 (0.56, 0.92) 1.11 (0.92, 1.33) 0.0056
Dist LN** 0.63 (0.48, 0.83) 1.29 (1.00, 1.67) 0.0002
*

p-value tests whether the effect of HER2 status varied significantly with HR status

**

Dist LN = distant lymph node

Numbers in parentheses are 95% confidence intervals for the hazard ratios.